Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019
01 août 2019 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Participate in Upcoming Healthcare Conferences
29 mai 2019 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics To Participate In Upcoming Healthcare Conferences
07 mai 2019 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019
02 mai 2019 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan
29 avr. 2019 07h40 HE
|
Immunomedics
The Largest Single-Asset License Agreement for Greater China To Date Provides Everest Medicines the Right to Develop and Commercialize Sacituzumab Govitecan for All Cancer Indications in Greater...
Immunomedics Announces Departure of Chief Medical Officer
29 avr. 2019 07h35 HE
|
Immunomedics
MORRIS PLAINS, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S.
08 avr. 2019 09h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Appoints Barbara G. Duncan to Board of Directors
07 mars 2019 16h01 HE
|
Immunomedics
MORRIS PLAINS, N.J., March 07, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...